1. Home
  2. CTMX vs DIN Comparison

CTMX vs DIN Comparison

Compare CTMX & DIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTMX
  • DIN
  • Stock Information
  • Founded
  • CTMX 2008
  • DIN 1958
  • Country
  • CTMX United States
  • DIN United States
  • Employees
  • CTMX N/A
  • DIN N/A
  • Industry
  • CTMX Biotechnology: Pharmaceutical Preparations
  • DIN Restaurants
  • Sector
  • CTMX Health Care
  • DIN Consumer Discretionary
  • Exchange
  • CTMX Nasdaq
  • DIN Nasdaq
  • Market Cap
  • CTMX 349.6M
  • DIN 379.1M
  • IPO Year
  • CTMX 2015
  • DIN 1991
  • Fundamental
  • Price
  • CTMX $1.93
  • DIN $24.35
  • Analyst Decision
  • CTMX Strong Buy
  • DIN Hold
  • Analyst Count
  • CTMX 4
  • DIN 9
  • Target Price
  • CTMX $5.13
  • DIN $26.57
  • AVG Volume (30 Days)
  • CTMX 2.4M
  • DIN 513.7K
  • Earning Date
  • CTMX 11-06-2025
  • DIN 11-05-2025
  • Dividend Yield
  • CTMX N/A
  • DIN 8.39%
  • EPS Growth
  • CTMX 263.20
  • DIN N/A
  • EPS
  • CTMX 0.49
  • DIN 2.99
  • Revenue
  • CTMX $141,100,000.00
  • DIN $845,368,000.00
  • Revenue This Year
  • CTMX N/A
  • DIN $11.28
  • Revenue Next Year
  • CTMX N/A
  • DIN $2.11
  • P/E Ratio
  • CTMX $3.98
  • DIN $8.14
  • Revenue Growth
  • CTMX 18.01
  • DIN 2.92
  • 52 Week Low
  • CTMX $0.40
  • DIN $18.63
  • 52 Week High
  • CTMX $3.10
  • DIN $37.44
  • Technical
  • Relative Strength Index (RSI)
  • CTMX 41.17
  • DIN 59.50
  • Support Level
  • CTMX $1.90
  • DIN $23.58
  • Resistance Level
  • CTMX $2.16
  • DIN $24.72
  • Average True Range (ATR)
  • CTMX 0.13
  • DIN 0.78
  • MACD
  • CTMX -0.01
  • DIN 0.16
  • Stochastic Oscillator
  • CTMX 7.50
  • DIN 78.17

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

About DIN Dine Brands Global Inc.

Dine Brands Global Inc owns and franchises thousands of restaurants under the Applebee's and International House of Pancakes names. Almost all company restaurants are located in the United States and franchised. Royalty revenue, which the company gets from franchisees based on franchisees' sales, accounts for roughly three-quarters of total company revenue. The company also earns revenue by leasing restaurant sites to franchisees. The company has four reportable segments Franchise operations, (an aggregation of Applebee's and IHOP franchise operations), Rental operations, Financing operations and Company-operated restaurant operations. The majority of revenue is derived from the Franchise operations segment.

Share on Social Networks: